伊曲康唑胶囊治疗婴幼儿血管瘤的临床疗效观察

Clinical observation of Itraconazole capsule in the treatment of infantile hemangioma

目的观察口服伊曲康唑胶囊治疗婴幼儿血管瘤的临床疗效及安全性。方法将评估为中风险的婴幼儿血管瘤患儿分为实验组和对照组,其中实验组口服伊曲康唑胶囊,对照组口服普洛萘尔片,选取(0～12)周为观察期,服药期间对两组患儿进行随访观察,定期复查血液学指标、瘤体多普勒超声、皮肤镜等检查。结果 12周后实验组有效率66.7%,对照组有效率100%。实验组瘤体消退速度较对照组慢,服药期间两组均未发现明显不良反应。结论口服伊曲康唑治疗婴幼儿血管瘤具有一定的作用,且服药期间未发现明显不良反应,其近期疗效不及口服普萘洛尔片。

Objective To observe the clinical efficacy and safety of oral itraconazole in the treatment of infants with hemangioma.Methods The children who were assessed as intermediate risk hemangioma were divided into the experimental group and the control group,between which the experimental group took itraconazole capsules orally and the control group took propranolol tablets orally.The observation period was(0~12)weeks.The children in the two groups were followed up for observation during the period of the medicine,and the hematological indicators,Doppler ultrasound of the tumor and skin microscopy were reviewed regularly.Results After 12 weeks,the effective rate was 66.7%in the experimental group and 100%in the control group.The regression rate of the tumor in the experimental group was slower than that in the control group.No hematological abnormalities or adverse reactions were found in the two groups during the drug administration.Conclusion Oral itraconazole has a certain effect in the treatment of hemangioma and no adverse reactions were found during the treatment.Its short-term efficacy is not as good as oral propranolol tablets.